Insulin Resistance and Diabetes: What a Continuous Glucose Monitor Can (and Can't) Tell You

Short Answer

Insulin resistance is the shared engine behind most type 2 diabetes: your muscle, fat, and liver cells stop responding to insulin as well as they should, so the pancreas has to push out more insulin to move glucose out of the bloodstream and into cells. For a while, that extra insulin can keep blood sugar looking “normal.” Then the system can start to slip — first into prediabetes, then, for some people, into type 2 diabetes. That’s why insulin resistance can be present for years before routine glucose numbers look clearly abnormal. (niddk.nih.gov)

Type 1 diabetes is different. It is not “more severe insulin resistance.” It is an autoimmune disease in which the immune system destroys insulin-producing cells in the pancreas, leaving the body with little or no insulin. Type 1 and type 2 diabetes can both raise blood glucose, but they do it through different biology, and they are not interchangeable. (niddk.nih.gov)

A continuous glucose monitor for diabetes (CGM) can help you see glucose patterns in real time — how your glucose rises after meals, drops overnight, or responds to activity — but it does not diagnose diabetes or insulin resistance by itself. Diagnosis still depends on clinician-ordered blood tests such as HbA1c, fasting plasma glucose, and sometimes an oral glucose tolerance test. In the ADA’s Standards of Care, the ranges include A1C 5.7%–6.4% for prediabetes and 6.5% or higher for diabetes, and fasting plasma glucose 100–125 mg/dL for prediabetes and 126 mg/dL or higher for diabetes. HOMA-IR can help estimate insulin resistance from fasting glucose and fasting insulin in clinical or research contexts, but insulin-resistance testing is used mainly in research rather than as a routine diagnostic test. (diabetes.org)

The useful part: insulin sensitivity can improve. Weight management, physical activity, food quality, sleep, and clinician-guided treatment can reduce metabolic strain; when appropriate, a clinician may prescribe medication such as metformin to help manage blood glucose and lower the risk of type 2 diabetes. Welltory does not measure blood glucose, so it cannot tell you whether you have diabetes, prediabetes, or insulin resistance — but patterns in resting heart rate, HRV, sleep, and stress may still give useful context to discuss with your clinician. (niddk.nih.gov)

Insulin resistance, prediabetes, and diabetes at a glance

Think of these as a metabolic timeline, not four interchangeable labels. Insulin resistance can come first: muscle, fat, and liver cells do not respond to insulin as efficiently as they should, so the pancreas has to release more insulin to keep glucose in range. At this compensated stage, your fasting glucose or A1C can still look “normal,” which is why clinicians may look at related signals such as fasting insulin, HOMA-IR, or the TyG index. These are surrogate markers, not stand-alone diagnoses; HOMA-IR uses fasting glucose and fasting insulin, while TyG uses fasting glucose and triglycerides, and evidence for TyG as an insulin-resistance marker is useful but not perfect. (my.clevelandclinic.org)

Prediabetes means that compensation is starting to slip. Blood sugar is higher than normal, but not high enough for a diabetes diagnosis. In clinician-ordered testing, the usual cutoffs are HbA1c 5.7–6.4% or fasting plasma glucose 100–125 mg/dL. These results are typically interpreted in a medical setting and may need confirmation, depending on the test and situation. (diabetes.org)

Type 2 diabetes usually reflects both insulin resistance and insulin output that is no longer enough for the body’s needs. It is flagged by blood-test thresholds such as HbA1c ≥6.5% or fasting plasma glucose ≥126 mg/dL; the ADA notes that diabetes testing is done in a health care setting and that results often need to be repeated unless glucose is very high with classic symptoms. A continuous glucose monitor can show glucose patterns, but it does not diagnose diabetes. (diabetes.org)

Type 1 diabetes is a separate pathway. It is not primarily insulin resistance. It happens when an autoimmune process damages insulin-producing beta cells, leaving the pancreas making little or no insulin; people with type 1 diabetes need insulin treatment. When the type of diabetes is unclear, clinicians may use diabetes-related autoantibodies and C-peptide, a marker of the body’s own insulin production, to help distinguish autoimmune diabetes from non-autoimmune type 2 diabetes. (cdc.gov)

How the tools compare: CGM, HbA1c, fasting glucose, HOMA-IR

What insulin resistance actually is

Insulin is the hormone that helps move glucose out of your blood and into muscle, liver, and fat cells, where it can be used for energy or stored for later. In insulin resistance, those cells still “hear” insulin — just less clearly. So your pancreas has to speak louder by releasing more insulin. For a while, that extra insulin can keep blood sugar in a normal range, which is why insulin resistance can be invisible: you may not feel anything, and a single glucose reading can look fine. If the pancreas can’t keep compensating, glucose starts to rise — first into the prediabetes range, and over time, for some people, into type 2 diabetes. (my.clevelandclinic.org)

That’s why insulin resistance isn’t captured well by blood sugar alone. When clinicians or researchers try to quantify it, they usually use surrogate markers — lab-based estimates of how hard the body is working to keep glucose controlled. One classic example is HOMA-IR, which estimates insulin resistance from fasting glucose and fasting insulin rather than from glucose alone. As one long-term cardiovascular study describes it, cardiovascular risk factors, metabolic syndrome, and insulin resistance were assessed “using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)” (Impact of Insulin Resistance and Preclinical Atherosclerosis Parameters in Long-Term Prediction of Cardiovascular Events, 2026). (pmc.ncbi.nlm.nih.gov)

Newer, simpler surrogates are also used because insulin resistance often shows up as a broader metabolic pattern, not just “high sugar.” The triglyceride-glucose, or TyG, index uses routine fasting triglyceride and glucose values and has been studied as a practical marker of insulin resistance and cardiometabolic risk — one review calls the “triglyceride-glucose (TyG) index a reliable marker of insulin resistance with predictive value for cardiovascular risk” (TyG index variability and cardiovascular mortality, 2026). (pmc.ncbi.nlm.nih.gov)

Why it matters — the link to type 2 diabetes and beyond

Insulin resistance is not just a lab concept. It is often an early pressure point in a larger metabolic pattern: your muscle, liver, and fat cells stop responding to insulin as cleanly, so your pancreas has to push out more insulin to move glucose out of the bloodstream. For a while, that extra insulin can keep blood sugar looking “normal.” But the workload is real, and it often travels with the same body-wide signals that raise risk for type 2 diabetes, fatty liver disease, cardiovascular disease, and kidney problems.

One reason obesity raises metabolic risk is that fat tissue is not passive storage. As fat cells enlarge and become stressed, immune cells can move into the tissue and inflammatory signaling rises. As one 2026 review puts it, “in obesity, chronic low-grade inflammation, marked by immune infiltration and dysregulated adipocyte function, contributes to systemic insulin resistance and metabolic comorbidities” (The Influence of Weight Loss and Weight Regain on Adipose Tissue Inflammation, 2026). (pmc.ncbi.nlm.nih.gov)

Insulin resistance also shows up in conditions that are not “just about weight.” In polycystic ovary syndrome, for example, insulin signaling and reproductive hormone signaling can reinforce each other: higher insulin can stimulate ovarian androgen production, while androgen excess and inflammation can worsen the metabolic picture. It is common in PCOS — one 2026 study reports that “insulin resistance (IR) is commonly observed in patients with polycystic ovary syndrome (PCOS), affecting 44% to 70% of these individuals” (Kisspeptin improves local ovarian insulin resistance in PCOS, 2026). (pmc.ncbi.nlm.nih.gov)

Prediabetes is often the point where this hidden workload becomes measurable on standard blood tests. It is not rare, and it is not a guaranteed sentence. In one large long-term cohort, “of the 60% of adults with prediabetes at baseline, ~30% progressed to diabetes (median time to diabetes, 7 years)” (Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes, 2025). (pmc.ncbi.nlm.nih.gov)

That matters because the risk does not begin only on the day someone crosses the diagnostic line for diabetes. In the same cohort, prediabetes — defined as “HbA1c 39-47 mmol/mol [5.7-6.4%] or fasting glucose 5.6-6.9 mmol/l” — was “associated with elevated risks of microvascular and macrovascular complications.” (pmc.ncbi.nlm.nih.gov)

At the population level, the burden is already large. The CDC’s National Diabetes Statistics Report estimates that 40.1 million people in the U.S. had diagnosed or undiagnosed diabetes in 2023 — 12.0% of the population — and that 115.2 million U.S. adults had prediabetes. Most diabetes in the U.S. is type 2 diabetes: CDC describes about 90% to 95% of diabetes cases as type 2. (cdc.gov) (cdc.gov)

Prevalence also varies sharply by country and region, so regional numbers should not be treated as global numbers. For example, a Saudi Arabian consensus paper reports that “Saudi Arabia has one of the highest prevalences of diabetes globally, with 16.4% of the population living with type 2 diabetes (T2D)” (Use of continuous glucose monitoring in non-intensively managed type 2 diabetes: a Saudi Arabian consensus, 2025). That figure is useful as a regional signal of burden, not as a worldwide estimate. (pmc.ncbi.nlm.nih.gov)

Type 1 vs type 2 — do not conflate them

This page is about insulin resistance, the body state that often sits upstream of prediabetes and type 2 diabetes. Type 2 usually begins with a mismatch: your muscle, fat, and liver cells stop responding to insulin as well as they should, the pancreas tries to compensate by making more, and blood glucose can rise when that compensation is no longer enough. Type 1 diabetes is a different disease. In type 1, the immune system attacks the pancreatic beta cells that make insulin, so the core problem is too little insulin, not “lifestyle-driven” insulin resistance. People with type 1 generally need insulin to manage blood glucose and stay alive; food, movement, and sleep still matter for day-to-day glucose control, but they do not reverse the autoimmune loss of insulin-producing cells. (niddk.nih.gov)

That distinction matters for how you read CGM patterns. A continuous glucose monitor can show highs, lows, timing, and variability in someone with type 1 or type 2, but it cannot tell you which type of diabetes you have or diagnose insulin resistance by itself. If a clinician needs to distinguish type 1 from type 2, they may use blood tests such as autoantibody testing along with glucose-based tests and clinical context. So when this article talks about insulin-resistance patterns, prediabetes, type 2 risk, or “reversal” of insulin resistance, read that as type 2/prediabetes language — not as a treatment frame for type 1 diabetes. (cdc.gov)

How it's diagnosed — and the numbers that define it

You can’t diagnose diabetes, prediabetes, or insulin resistance from how you feel, from one home reading, or from a continuous glucose monitor graph. Diagnosis uses clinician-ordered blood tests, usually done in a health care setting, and the result may need confirmation with repeat testing unless blood sugar is unmistakably high with classic symptoms. These cutoffs are used by a clinician for screening and diagnosis — not for self-diagnosis. (diabetes.org)

For diabetes, the current ADA Standards of Care use defined laboratory cutoffs: A1C ≥6.5%, fasting plasma glucose ≥126 mg/dL, 2-hour oral glucose tolerance test glucose ≥200 mg/dL, or random plasma glucose ≥200 mg/dL in someone with classic hyperglycemia symptoms or hyperglycemic crisis. (pmc.ncbi.nlm.nih.gov) A widely used combined research definition says the same thing in compact form: type 2 diabetes incidence “was defined as fasting blood glucose level ≥126 mg/dL, glycated hemoglobin level ≥6.5%, or self-reported initiation of glucose-lowering medications” (Aichi Worker’s Cohort Study, 2026). The prediabetes band sits just below diabetes — “HbA1c 39-47 mmol/mol [5.7-6.4%] or fasting glucose 5.6-6.9 mmol/l” — and the ADA diagnostic range for prediabetes includes A1C 5.7–6.4% and fasting plasma glucose 100–125 mg/dL. (pmc.ncbi.nlm.nih.gov)

Insulin resistance is trickier because it can build for years before fasting glucose crosses a diagnostic line. Your muscles, liver, and fat cells may need more insulin to move the same amount of glucose out of the blood; early on, the pancreas may compensate by making more insulin, so glucose can still look “normal.” That’s why insulin resistance is often estimated with surrogate indices such as HOMA-IR, which uses fasting insulin and fasting glucose, or the TyG index, which uses fasting triglycerides and fasting glucose — not by a single glucose value alone. (my.clevelandclinic.org)

Can a CGM or wearable tell me if I'm insulin resistant?

A continuous glucose monitor for diabetes can show you the shape of your glucose day: how quickly glucose rises after meals, how long it stays elevated, whether it dips, and what happens overnight. That visibility can be genuinely useful, especially if you already have diabetes or are working with a clinician on glucose management, because CGMs track glucose continuously through interstitial fluid instead of giving only a single finger-stick snapshot. But a pattern is not a diagnosis. Prediabetes and diabetes are diagnosed with standardized blood tests such as A1C, fasting plasma glucose, or an oral glucose tolerance test, done and interpreted in a healthcare setting; insulin resistance itself is also difficult to diagnose routinely and cannot be confirmed by a CGM alone. (cdc.gov)

So if your CGM shows big post-meal swings, frequent highs, or confusing lows, treat that as a reason to ask for proper testing — not as proof that you are insulin resistant, and not as proof you are “fine” if the graph looks calm. Glucose is only one layer of the system. Sleep loss, stress, illness, medication effects, exercise timing, and what you ate yesterday can all change the day’s curve. Wearables sit one step further away: heart rate, heart-rate variability, sleep, and stress signals can reflect autonomic load and recovery strain, but they are not glucose values and cannot diagnose insulin resistance, prediabetes, or diabetes. Welltory does not measure blood glucose at all. The FDA has warned that smartwatches and smart rings should not be used to measure or estimate blood glucose on their own. (fda.gov)

What helps — lifestyle first, medication when a clinician decides

The encouraging part: insulin resistance is often improvable. Your cells are not “broken”; they are struggling to respond to insulin’s signal. Regular movement can make muscle more sensitive to insulin, weight loss can reduce the metabolic strain if you have overweight or obesity, and a balanced eating pattern can lower the glucose load your pancreas has to manage. Sleep and stress matter too, because the hormones that keep you alert can also push glucose and insulin demand upward. CDC describes insulin resistance as something that can often be improved by making cells more sensitive to insulin through these kinds of changes. (cdc.gov)

And the changes are not only theoretical — they can show up in markers. In one one-year intensive lifestyle intervention program in people with type 2 diabetes, the group that reached remission had larger improvements in body weight, HbA1c, fasting insulin, and HOMA-IR than the group that did not: it “showed significantly greater improvements in weight (-8.5% vs. -5.2%), BMI (-8.6% vs. -5.2%), HbA1c (-15.3% vs. -12.4%), fasting insulin (-26.6% vs. -11.4%), and homeostatic model assessment of insulin resistance (HOMA-IR) (-37.3% vs. -19.7%), than the non-remission group (p <0.05)” (Type 2 diabetes remission in an Indian cohort, 2026). (pmc.ncbi.nlm.nih.gov) Dietary pattern matters too, because food changes the mix of glucose exposure, liver fat pressure, gut-microbiome signals, inflammation, and lipids your body has to handle after meals. A Mediterranean-style pattern has been studied across randomized trials, with reported improvements in inflammatory and metabolic markers: one review notes that “Mediterranean dietary interventions reduce hs-CRP by 18-32%, increase microbiome diversity by 6-28%, and improve metabolic markers including HOMA-IR and TG/HDL ratios” (A Conceptual Digital Health Framework for Longevity Optimization, 2026). (pmc.ncbi.nlm.nih.gov)

Medication is different. Lifestyle is something you can start shaping; medication is a medical decision. The drug class, timing, safety checks, and dose depend on your diagnosis, A1c, kidney function, cardiovascular risk, weight goals, other medications, pregnancy plans, side-effect risk, and what your clinician is trying to prevent — they are individualized by a clinician, and you should not start or self-adjust any medication without medical guidance. ADA’s pharmacologic guidance says glucose-lowering therapy should be chosen and adjusted around individualized glycemic and weight goals, comorbidities, and hypoglycemia risk, with regular reevaluation. This article gives no doses. (diabetes.org)

As background on the most common first-line option, one 2026 review describes “metformin, an oral antihyperglycemic drug,” as “the cornerstone of pharmacological treatment for type 2 diabetes mellitus (T2DM),” adding that “beyond its direct impact on glucose metabolism, metformin also improves insulin sensitivity and has beneficial effects on lipid profiles” (From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin, 2026). (pmc.ncbi.nlm.nih.gov) MedlinePlus describes metformin as a biguanide used for type 2 diabetes that lowers glucose production by the liver, reduces glucose absorbed from food, and increases the body’s response to insulin. (medlineplus.gov)

Metformin and other glucose-lowering agents — including SGLT2 inhibitors and GLP-1 receptor agonists such as semaglutide — are prescription medicines. Whether any of them is appropriate for you, and at what dose, is decided by a clinician, not by an app or article. We give no doses here. The FDA describes SGLT2 inhibitors as prescription medicines used with diet and exercise to lower blood sugar in adults with type 2 diabetes, and FDA materials identify semaglutide as part of the GLP-1 receptor agonist class used for diabetes and/or weight-related indications depending on the product. (fda.gov)

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data